



Anonymous Cancer Center  
Summary Report of Wipe Sample Analysis for Hazardous Drugs (HDs)

Department/BLD/Rm: Pharmacy

Date Reported: May 07, 2020

AA Project: P00XXX02

Units: ng/cm<sup>2</sup> (ng/ft<sup>2</sup>)

AA ID	BD23001-01	BD23001-02	BD23001-03	BD23001-04	BD23001-05	BD23001-06
Client ID	1	2	3	4	5	6
Location	Wall Office Left	Wall Office Right	Floor Office	Purchasing Desk	Pharmacist Check Counter	Pharmacy Window
5-Fluorouracil	ND	ND	ND	ND	ND	ND
Cyclophosphamide	ND	ND	ND	ND	ND	ND
Cytarabine	ND	ND	ND	ND	ND	ND
Docetaxel	ND	ND	ND	ND	ND	ND
Doxorubicin	ND	ND	ND	ND	ND	ND
Etoposide	ND	ND	ND	ND	ND	ND
Gemcitabine	ND	ND	ND	ND	ND	ND
Ifosfamide	ND	ND	ND	ND	ND	ND
Methotrexate	ND	ND	ND	ND	ND	ND
Mitomycin C	ND	ND	ND	ND	ND	ND
Paclitaxel	ND	ND	ND	ND	ND	ND
Platinum Analogues	ND	ND	ND	ND	ND	ND
Vincristine	ND	ND	ND	ND	ND	ND

**Stuart Sigman**  
Project Manager  
(818) 998-5546 Ext. 308

Notes:

- 1. Please refer to the attached report for details including the Method Reporting Limit (MRL).
- 2. Green color indicates ND or Not Detected. Orange color indicates detectable concentration of the analyte.



Anonymous Cancer Center  
Summary Report of Wipe Sample Analysis for Hazardous Drugs (HDs)

Department/BLD/Rm: Pharmacy

Date Reported: May 07, 2020

AA Project: POXXX02

Units: ng/cm<sup>2</sup> (ng/ft<sup>2</sup>)

AA ID	BD23001-07	BD23001-08	BD23001-09	BD23001-10	BD23001-11	BD23001-12
Client ID	7	8	9	10	11	12
Location	BSC New	Pass Thru	Haz. Room Staging Cart	BSC Old	Bench in Haz. Room	Lap Top Keyboard Haz. Rm.
5-Fluorouracil	ND	ND	0.076 (70)	ND	0.11 (99)	ND
Cyclophosphamide	ND	ND	ND	ND	ND	ND
Cytarabine	ND	ND	ND	ND	ND	ND
Docetaxel	ND	ND	ND	ND	ND	ND
Doxorubicin	ND	ND	ND	ND	ND	ND
Etoposide	ND	ND	ND	ND	ND	ND
Gemcitabine	ND	ND	ND	ND	ND	ND
Ifosfamide	ND	ND	ND	ND	ND	ND
Methotrexate	ND	ND	ND	ND	ND	ND
Mitomycin C	ND	ND	ND	ND	ND	ND
Paclitaxel	ND	ND	ND	ND	ND	ND
Platinum Analogues	ND	ND	ND	ND	ND	ND
Vincristine	ND	ND	ND	ND	ND	ND

**Stuart Sigman**  
Project Manager  
(818) 998-5546 Ext. 308

Notes:

- 1. Please refer to the attached report for details including the Method Reporting Limit (MRL).
- 2. Green color indicates ND or Not Detected. Orange color indicates detectable concentration of the analyte.



9765 Eton Avenue  
Chatsworth  
California 91311  
Tel: (818) 998-5547  
Fax: (818) 998-7258

---

May 07, 2020

XXXXX XXXXXX

Anonymous Cancer Center

100 Main St.

Somewhere, XX 12345

**Re : Pharmacy**

Enclosed is an analytical report for the above-referenced project. The samples included in this report were received on 04/23/20 13:54 and analyzed in accordance with the attached chain-of-custody.

Unless otherwise noted, all analytical testing was accomplished in accordance with the guidelines established in our Quality Assurance Program Manual, applicable standard operating procedures, and other related documentation. The results in this analytical report are limited to the samples tested and any reproduction thereof must be made in its entirety.

If you have any questions regarding this report or require additional information please call me at American Analytix.

Sincerely,

A handwritten signature in black ink, appearing to read 'Stuart Sigman', is written over a light blue horizontal line.

Stuart Sigman

Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** N/A  
**Project Name:** Pharmacy

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20

Sample ID	Laboratory ID	Matrix	TAT	Date Sampled	Date Received
-----------	---------------	--------	-----	--------------	---------------

#### Cytotoxic Drugs by LCMSMS

1 - Wall Office Left	BD23001-01	Wipe	10	04/22/20 13:30	04/23/20 13:54
2 - Wall Office Right	BD23001-02	Wipe	10	04/22/20 13:34	04/23/20 13:54
3 - Floor Office	BD23001-03	Wipe	10	04/22/20 13:36	04/23/20 13:54
4 - Purchasing Desk	BD23001-04	Wipe	10	04/22/20 13:43	04/23/20 13:54
5 - Pharmacist Check Counter	BD23001-05	Wipe	10	04/22/20 13:47	04/23/20 13:54
6 - Pharmacy Window	BD23001-06	Wipe	10	04/22/20 13:49	04/23/20 13:54
7 - BSC New	BD23001-07	Wipe	10	04/22/20 14:00	04/23/20 13:54
8 - Pass Thru	BD23001-08	Wipe	10	04/22/20 13:55	04/23/20 13:54
9 - Haz. Room Staging Cart	BD23001-09	Wipe	10	04/22/20 13:50	04/23/20 13:54
10 - BSC Old	BD23001-10	Wipe	10	04/22/20 14:10	04/23/20 13:54
11 - Bench in Haz. Room	BD23001-11	Wipe	10	04/22/20 14:15	04/23/20 13:54
12 - Lap Top Keyboard Haz. Rm.	BD23001-12	Wipe	10	04/22/20 14:20	04/23/20 13:54

#### Cytotoxic Platinum Analogues by LCMSMS

1 - Wall Office Left	BD23001-01	Wipe	10	04/22/20 13:30	04/23/20 13:54
2 - Wall Office Right	BD23001-02	Wipe	10	04/22/20 13:34	04/23/20 13:54
3 - Floor Office	BD23001-03	Wipe	10	04/22/20 13:36	04/23/20 13:54
4 - Purchasing Desk	BD23001-04	Wipe	10	04/22/20 13:43	04/23/20 13:54

**Stuart Sigman**  
Project Manager

**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy

**AA Project No:** P00XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20

Sample ID	Laboratory ID	Matrix	TAT	Date Sampled	Date Received
5 - Pharmacist Check Counter	BD23001-05	Wipe	10	04/22/20 13:47	04/23/20 13:54
6 - Pharmacy Window	BD23001-06	Wipe	10	04/22/20 13:49	04/23/20 13:54
7 - BSC New	BD23001-07	Wipe	10	04/22/20 14:00	04/23/20 13:54
8 - Pass Thru	BD23001-08	Wipe	10	04/22/20 13:55	04/23/20 13:54
9 - Haz. Room Staging Cart	BD23001-09	Wipe	10	04/22/20 13:50	04/23/20 13:54
10 - BSC Old	BD23001-10	Wipe	10	04/22/20 14:10	04/23/20 13:54
11 - Bench in Haz. Room	BD23001-11	Wipe	10	04/22/20 14:15	04/23/20 13:54
12 - Lap Top Keyboard Haz. Rm.	BD23001-12	Wipe	10	04/22/20 14:20	04/23/20 13:54

---

---

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Wall Paint

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**1 - Wall Office Left**

**BD23001-01 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Wall Paint

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**2 - Wall Office Right**

**BD23001-02 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Tile

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**3 - Floor Office**  
**BD23001-03 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager





**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**4 - Purchasing Desk**

**BD23001-04 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**5 - Pharmacist Check Counter**  
**BD23001-05 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**6 - Pharmacy Window**  
**BD23001-06 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**7 - BSC New**  
**BD23001-07 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**8 - Pass Thru**  
**BD23001-08 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

### 9 - Haz. Room Staging Cart

#### BD23001-09 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<b>17</b>	ng	10	<b>70</b>	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
 Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**10 - BSC Old**  
**BD23001-10 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

**11 - Bench in Haz. Room**  
**BD23001-11 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<b>24</b>	ng	10	<b>99</b>	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager





## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Plastic

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 04/30/20  
**Area:** 0.242 ft<sup>2</sup>

### 12 - Lap Top Keyboard Haz. Rm.

#### BD23001-12 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Docetaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cytarabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Ifosfamide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Etoposide	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Methotrexate	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Vincristine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Gemcitabine	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Mitomycin C	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
 Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Wall Paint

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

1 - Wall Office Left

BD23001-01 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager

**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Wall Paint

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**2 - Wall Office Right**

**BD23001-02 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager

**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Tile

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**3 - Floor Office**  
**BD23001-03 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**4 - Purchasing Desk**

**BD23001-04 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager

**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**5 - Pharmacist Check Counter****BD23001-05 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager

**LABORATORY ANALYSIS RESULTS**

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Counter

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**6 - Pharmacy Window****BD23001-06 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**7 - BSC New**  
**BD23001-07 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager





### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**8 - Pass Thru**  
**BD23001-08 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**9 - Haz. Room Staging Cart**

**BD23001-09 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

**10 - BSC Old**  
**BD23001-10 (Wipe)**

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



### LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Stainless Steel

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

11 - Bench in Haz. Room

BD23001-11 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
Project Manager



## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Plastic

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20  
**Sampled:** 04/22/20  
**Prepared:** 04/30/20  
**Analyzed:** 05/05/20  
**Area:** 0.242 ft<sup>2</sup>

12 - Lap Top Keyboard Haz. Rm.

BD23001-12 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Platinum Analogues	<10	ng	10	<41	ng/ft <sup>2</sup>	41

**Stuart Sigman**  
 Project Manager



## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20

Analyte	Result	Reporting Limit	Units	Spike Source Level	Source Result	%REC %REC	%REC Limits	RPD	RPD Limit	Notes
<b>Cytotoxic Drugs by LCMSMS - Quality Control</b>										
<i>Batch P0E0101 - Methanol Extraction</i>										
<b>Blank (P0E0101-BLK1)</b>				Prepared & Analyzed: 04/30/20						
Docetaxel	<10	10	ng							
Paclitaxel	<10	10	ng							
Doxorubicin	<10	10	ng							
5-Fluorouracil	<10	10	ng							
Cyclophosphamide	<10	10	ng							
Cytarabine	<10	10	ng							
Ifosfamide	<10	10	ng							
Etoposide	<10	10	ng							
Methotrexate	<10	10	ng							
Vincristine	<10	10	ng							
Gemcitabine	<10	10	ng							
Mitomycin C	<10	10	ng							
<i>Batch P0E0501 - Methanol Extraction</i>										
<b>Blank (P0E0501-BLK1)</b>				Prepared: 04/30/20 Analyzed: 05/05/20						
Platinum Analogues	<10	10	ng							

**Stuart Sigman**  
 Project Manager



## LABORATORY ANALYSIS RESULTS

**Client:** Anonymous  
**Project No:** NA  
**Project Name:** Pharmacy

**AA Project No:** P0XXX02  
**Received:** 04/23/20  
**Reported:** 05/07/20

---

### Special Notes

---

A handwritten signature in black ink, appearing to read 'Stuart Sigman'.

---

**Stuart Sigman**  
Project Manager



**LABORATORY ANALYSIS RESULTS**


1  
**Client:** XXXXXXCancer Center  
**Project No.:** NA  
**Project Name:** Cancer Center  
**Matrix:** Wipe  
**Dilution:** 1  
**Method:** Cytotoxic Drugs by LCMSMS  
**Surface:** Plastic

2  
**AA Project No.:** PXXXXXX  
**Received:** 12/17/19  
**Reported:** 01/07/20  
**Sampled:** 12/13/19  
**Prepared:** 12/17/19  
**Analyzed:** 12/17/19  
**Area:** 0.242 ft<sup>2</sup>

2 - Transfer Bin  
 AL17004-02 (Wipe)

Analyte	Result	Units	MRL	Result	Units	MRL
Paclitaxel	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Doxorubicin	<10	ng	10	<41	ng/ft <sup>2</sup>	41
5-Fluorouracil	<10	ng	10	<41	ng/ft <sup>2</sup>	41
Cyclophosphamide	710 **	ng	100	2900 **	ng/ft <sup>2</sup>	410

7 This section presents the analytical results in mass per unit area. In this example it's expressed as Nano-grams (ng) per square foot (ft<sup>2</sup>); "<41 ng/ft<sup>2</sup>" means that the HD was not detected. (ND)

  
 Stuart Sigman  
 Project Manager

- 1 **Client:** Entity name as entered on the Chain of Custody (COC)  
**Project No.:** Client project number, if provided on the COC  
**Project Name:** as entered on the COC under Dept/Bldg/Room  
**Matrix:** describes sample type, including wipe, liquid, solid, etc.  
**Dilution:** Sometimes the wipe sample extract is diluted in order to reduce interference. When this happens, the sample is combined with additional solvent. This process is called dilution. Dilution results in proportional elevation on the MRL (See MRL definition below).  
**Method:** The analytical method used to analyze the sample(s)  
**Surface:** surface material sampled as indicated on the COC
- 2 **AA Project No.:** American Analytics (AA) assigns a unique internal project number for every sample submission event.  
**Received:** Date samples received at AA  
**Reported:** Date this lab report was generated  
**Sampled:** Date samples were collected as entered on the COC  
**Prepared:** Date samples were prepared for analysis at AA  
**Analyzed:** Date samples were analyzed at AA  
**Area:** total area wiped as calculated based on information provided on the COC
- 3 **Sample ID:** Client's sample ID as designated on the COC. The Lab internal sample *ID appears below the Client sample ID.*
- 4 List of hazardous drugs analyzed per client's request on the COC
- 5 The "Result" number is the total Hazardous Drug's (HD) mass, in Nano-grams (ng), found on the wipe sample itself. In this example: "<10 ng", means that the HD was Not Detected (ND)
- 6 **MRL:** Method Reporting Limit is the minimum amount or concentration of an HD that can be quantitatively measured with acceptable and defensible precision and accuracy. In this example, a result of "<10 ng" indicates no HD was detected at or above the MRL of 10 ng.  
**ND:** Results below the MRL are defined as "Non-Detectable" concentrations (shown in the summary report as (ND)).